OligomenorrheaNCT01927432
Ultrasound Characterization of Ovarian Follicle Dynamics in Women With Amenorrhea
An observational study of Oligomenorrhea and Amenorrhea, run by Cornell University at 1 site in United States.
Trial summary
In women with regular menstrual cycles, antral follicles have been shown to grow in synchronous cohorts, called waves, 2-3 times in a menstrual cycle. It is unknown whether these waves of follicle growth also occur in women with amenorrhea or if there is abnormal/absent follicle growth. Read more about this study
- Who is it for?
- Ages 18 to 35 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Oligomenorrhea, Amenorrhea, Polycystic Ovary Syndrome (PCOS)
- How many people
- 73 participants
- Where
- 1 siteUnited States
- Study dates
- Sep 2011to Sep 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- Women only
- Healthy volunteers accepted
- Adult
Study population: Women must be able to transport to Cornell University in Ithaca, NY. Eligible participants are between 18-35 years with a BMI of 18 kg/m2 or higher. Women are screened and enrolled following consent based on their response to our advertisements. Enrollment is restricted to the geographical area.
Who may be able to join
- Between 18 and 35 years
- BMI ≥ 18 kg/m2
- If ≥ 21 years old, must have had healthy pelvic exam w/in past 2 years
- Either:
- Regular menstrual cycles (21-35 days);
- Irregular menstrual cycles (>36 days) with or without a previous diagnosis of PCOS from a primary care provider
Who cannot join
- Current use of medication(s) known or suspected to interfere with reproductive function (eg. oral contraceptives) or insulin sensitivity
- Pregnant or breastfeeding
- Not otherwise healthy
Trial locations and contacts
1 site in 1 country.
United States1 site
Human Metabolic Research Unit, Cornell University
Ithaca, New York, 14853
About this study
In women with regular menstrual cycles, antral follicles have been shown to grow in synchronous cohorts, called waves, 2-3 times in a menstrual cycle. It is unknown whether these waves of follicle growth also occur in women with amenorrhea or if there is abnormal/absent follicle growth. Further, oligo- or amenorrhea has been associated with metabolic disturbances, such as over- or under-nutrition, central obesity and insulin resistance. Yet, mechanisms whereby metabolic factors influence folliculogenesis in women are poorly understood. To understand potential mechanisms, the investigators plan to characterize follicle growth dynamics in women with or without regular menstrual cycles and identifying key metabolic differences in these women which may be important in normal follicle development and fertility.
Read the detailed description
In the ovaries, eggs rest in fluid filled sacs called follicles. When follicles grow they form small fluid-filled cysts that can be easily seen when we use ultrasound to view the ovaries. In women with regular menstrual cycles, groups of 10 to 20 follicles grow and regress at 2 or 3 different times during their cycle (usually over a 28- day period). Several of these follicles grow to a stage where they begin to develop the potential to ovulate - but in general only one follicle is chosen to ovulate. Thus, at any given time during the menstrual cycle, numerous fluid-filled follicles can be visualized in a woman's ovaries at various stages of development using transvaginal ultrasonography. In women with absent or infrequent menstrual cycles, very little is known about the growth patterns of their follicles and how factors such as metabolic hormones, might play a role in the failure to ovulate. Being underweight or overweight increases your chances of having irregular or absent menstrual cycles and that a history of abnormal reproductive function compounds a woman's risk for chronic diseases such as infertility, diabetes, hypertension, atherosclerosis and certain cancers. This is particularly the case for women with polycystic ovary syndrome (PCOS) that have menstrual cycles that appear to worsen or improve depending on their body weight and metabolic status. PCOS is an endocrine disorder that affects 6-12% of reproductive-aged women within the general population. The hallmark features of PCOS are menstrual irregularity, increased levels of androgens, and polycystic ovaries. The current diagnostic criteria require 2 out of 3 of these features to be present for the diagnosis, therefore a number of phenotypes of PCOS exist. However, the metabolic and reproductive differences across the phenotypic spectrum of PCOS are not well understood. Women with PCOS characteristically have polycystic ovaries, where up to 10 times more follicles are present in the ovary at any given time. Further, the follicle-size populations and overall distribution throughout the ovary varies in women - follicles may be situated around the periphery of the ovary or may be distributed throughout the ovary. Presumably these small follicles are arrested in development - but emerging data from the Lujan laboratory suggest that this is not the case. It is assumed that ovulation does not occur and that follicles do not grow in a normal wave pattern. In truth, no study has ever looked to see whether follicles are actually growing, regressing or are arrested in women with irregular/absent menstrual cycles. By comparing follicle wave dynamics, reproductive hormones and markers of metabolism in women with regular and irregular menstrual cycles, the researchers plan to identify what factors might explain why fertility potential and long-term health are compromised in some women but not in others. Further, we will determine if any of these metabolic factors are unique to PCOS representing specific metabolic risks or follicle growth impairment. The ultimate goal of this research is to understand how body composition, nutrition and metabolism regulate follicle development in women so we can better develop lifestyle and drug therapies to help women preserve their fertility and long-term health. Since obesity has recently become the leading cause of infertility in North America, these studies are especially important.
To accomplish our objective, the investigators plan to recruit up to 40 women with regular menstrual cycles and up to 40 women with irregular/absent menstrual cycles. Our goal is to recruit an equal number of women in each group such that they are matched for age (18 - 35 years old) and body mass index (BMI; Normal weight = 18 - 24 kg/m2; Overweight = 25 - 29 kg/m2; Obese = 30kg/m2). Women will undergo serial ultrasonographic of their ovaries every other day from ovulation to ovulation in women with regular menstrual cycles or for 5 weeks in women with cycle irregularity. Blood samples will be collected at each visit. Ultrasound scans of the ovaries will be assessed for the total number, size, and distribution of follicles using ultrasound imaging techniques. Blood samples collected will be assayed to determine serum concentrations of luteinizing hormone (LH), follicle stimulating hormone (FSH), estradiol, progesterone, anti-müllerian hormone (AMH), and inhibin B. During day 3-5 in women with regular menstrual cycles or at a time where no dominant follicle or corpus luteum is present, an early morning visit will be conducted to assess the following metabolic parameters : (1) 75-gram oral glucose tolerance test to characterize glucose and insulin dynamics at 0, 30, 60, 90, and 120 minutes post-glucose ingestion; (2) dual X-ray absorptiometry (DXA) scan to quantify body fat and lean muscle distribution; (3) vitals and anthropometry assessment to measure waist and hip circumference, height, weight, blood pressure, and heart rate, and (4) fasting blood tests to detect serum concentrations of androgens (i.e., total testosterone, androstenedione, free androgen index) and serum markers of metabolic syndrome (i.e., lipids and hemoglobin A1C); (5) optional subcutaneous fat biopsy to analyze fat cells, which represent a site of reproductive hormone synthesis.
- Conditions
- Oligomenorrhea, Amenorrhea, Polycystic Ovary Syndrome (PCOS)
- Keywords
- Polycystic Ovary Syndrome (PCOS), Nutrition, Metabolism, Antral follicle growth, Menstrual Cyclicity
- Medical subject headings
- Oligomenorrhea, Amenorrhea, Polycystic Ovary Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Regular menstrual cycles | Adult women will be assigned to this category if they report a history of regular menstrual cycles. | |
| Irregular menstrual cycles | Adult women will be assigned to this category if they report a history of irregular menstrual cycles, including women with a pre-existing diagnosis of PCOS. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Follicle number
The number of all antral follicles in each ovary will be determined using ultrasonography for each participant. Changes in follicle number over time will be compared between groups.
Measured: 4-5 weeks
Follicle diameter
The diameter of all follicles >2mm will be determined using ultrasonography for each participant. Changes in follicle diameter over time will be compared between groups.
Measured: 4-5 weeks
Secondary outcomes (16)
Ovarian Volume
The size of each ovary will be determined using ultrasonography for each participant during study participation and compared between groups.
Measured: 4-5 weeks
Anti-Müllerian hormone
The serum AMH concentration will be determined during study participation and assessed in association with the change in follicle number, diameter and between groups.
Measured: 4-5 weeks
Serum FSH concentration
The serum FSH concentration will be determined during study participation and assessed in association with the change in follicle number, diameter and between groups.
Measured: 4-5 weeks
Serum LH concentration
The serum FSH concentration will be determined during study participation and assessed in association with the change in follicle number, diameter and between groups.
Measured: 4-5 weeks
Serum progesterone concentration
The serum progesterone concentration will be determined during study participation, assessed in association with luteal dynamics and compared between groups.
Measured: 4-5 weeks
LH-FSH ratio
The ratio of circulating LH to FSH concentrations will be determined for each participant and compared between groups.
Measured: 4-5 weeks
Insulin sensitivity
Insulin sensitivity will be determined by administration of an oral glucose tolerance test and compared between groups.
Measured: 1 day
Androgen concentrations
Total testosterone, androstenedione and free androgen index concentrations in serum will be determined and compared between groups.
Measured: 1 day
Menstrual Cycle Length
Average menstrual cycle length as determined by self-reported history and the menstrual cycle length during study participation will be determined and compared between groups.
Measured: 4-5 weeks
Hirsutism
Degree of hirsutism as judged by the Ferriman-Gallwey scale will be determined and compared between groups.
Measured: 1 day
Serum markers of metabolic syndrome
Lipids, glucose and HbA1C concentrations will be determined and compared between groups.
Measured: 1 day
Blood Pressure
Blood pressure will be determined and compared between groups.
Measured: 1 day
Body mass index
The ratio of weight to height will be determined and compared between groups.
Measured: 1 day
Waist-to-hip ratio
The ratio of waist circumference to hip circumference will be determined and compared between groups.
Measured: 1 day
Body fat distribution
Percentage and distribution of fat and lean mass as assessed using DXA technology will be compared between groups.
Measured: 1 day
Subcutaneous fat biopsy (optional)
Fat cells, representing an important site of reproductive hormone production, will be compared between groups.
Measured: 1 day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Aug 2013 (estimated)
- Study startSep 2011
- Primary completionSep 2021
- Study completionSep 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for OligomenorrheaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 73 participants (actual)
Sponsor and investigators
- Lead sponsor
- Cornell University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Marla E. Lujan, PhD, Principal investigator, Cornell University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01927432
- Sponsor's protocol ID
- IRB #: 0908000633
- Status last verified
- Feb 2024
- First submitted
- 20 Aug 2013
- Last updated
- 9 Feb 2024
- Results posted
- No
- Data monitoring committee
- No
Publications
Evans AT, Rehani E, Smith B, Hong MD, Lewin Z, Hiroshige K, Spandorfer SD, Hajirasouliha I, Lujan ME, Hoeger KM. Diagnosis of Polycystic Ovary Syndrome With Predictive Modeling of Select Clinical Features. O G Open. 2026 Mar 19;3(2):e161. doi: 10.1097/og9.0000000000000161. eCollection 2026 Apr.
PubMed 41868592Oldfield AL, Carter FE, Reeves RE, Jarrett BY, Vanden Brink H, Lujan ME. Impact of a hypocaloric dietary intervention on antral follicle dynamics in eumenorrheic women with obesity. Hum Reprod. 2024 Apr 3;39(4):801-811. doi: 10.1093/humrep/deae017.
PubMed 38335228Oldfield AL, Vanden Brink H, Carter FE, Jarrett BY, Lujan ME. Obesity is associated with alterations in antral follicle dynamics in eumenorrheic women. Hum Reprod. 2023 Mar 1;38(3):459-470. doi: 10.1093/humrep/dead007.
PubMed 36708012
Study at a glance
From the registry record, last updated by the sponsor on 9 Feb 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Ultrasound Characterization of Ovarian Follicle Dynamics in Women With Amenorrhea
- ClinicalTrials.gov ID
- NCT01927432
- Acronym / sponsor ID
- IRB #: 0908000633
- Conditions
- Oligomenorrhea, Amenorrhea, Polycystic Ovary Syndrome (PCOS)
- Keywords
- Polycystic Ovary Syndrome (PCOS), Nutrition, Metabolism, Antral follicle growth, Menstrual Cyclicity
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 73 participants (actual)
- Lead sponsor
- Cornell UniversityUniversity, hospital or other
- Study start
- Sep 2011
- Primary completion
- Sep 2021 (actual)
- Study completion
- Sep 2021 (actual)
- First posted
- 22 Aug 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In women with regular menstrual cycles, antral follicles have been shown to grow in synchronous cohorts, called waves, 2-3 times in a menstrual cycle. It is unknown whether these waves of follicle growth also occur in women with amenorrhea or if there is abnormal/absent follicle growth. Further, oligo- or amenorrhea has been associated with metabolic disturbances, such as over- or under-nutrition, central obesity and insulin resistance. Yet, mechanisms whereby metabolic factors influence folliculogenesis in women are poorly understood. To understand potential mechanisms, the investigators plan to characterize follicle growth dynamics in women with or without regular menstrual cycles and identifying key metabolic differences in these women which may be important in normal follicle development and fertility.
Detailed description
In the ovaries, eggs rest in fluid filled sacs called follicles. When follicles grow they form small fluid-filled cysts that can be easily seen when we use ultrasound to view the ovaries. In women with regular menstrual cycles, groups of 10 to 20 follicles grow and regress at 2 or 3 different times during their cycle (usually over a 28- day period). Several of these follicles grow to a stage where they begin to develop the potential to ovulate - but in general only one follicle is chosen to ovulate. Thus, at any given time during the menstrual cycle, numerous fluid-filled follicles can be visualized in a woman's ovaries at various stages of development using transvaginal ultrasonography. In women with absent or infrequent menstrual cycles, very little is known about the growth patterns of their follicles and how factors such as metabolic hormones, might play a role in the failure to ovulate. Being underweight or overweight increases your chances of having irregular or absent menstrual cycles and that a history of abnormal reproductive function compounds a woman's risk for chronic diseases such as infertility, diabetes, hypertension, atherosclerosis and certain cancers. This is particularly the case for women with polycystic ovary syndrome (PCOS) that have menstrual cycles that appear to worsen or improve depending on their body weight and metabolic status. PCOS is an endocrine disorder that affects 6-12% of reproductive-aged women within the general population. The hallmark features of PCOS are menstrual irregularity, increased levels of androgens, and polycystic ovaries. The current diagnostic criteria require 2 out of 3 of these features to be present for the diagnosis, therefore a number of phenotypes of PCOS exist. However, the metabolic and reproductive differences across the phenotypic spectrum of PCOS are not well understood. Women with PCOS characteristically have polycystic ovaries, where up to 10 times more follicles are present in the ovary at any given time. Further, the follicle-size populations and overall distribution throughout the ovary varies in women - follicles may be situated around the periphery of the ovary or may be distributed throughout the ovary. Presumably these small follicles are arrested in development - but emerging data from the Lujan laboratory suggest that this is not the case. It is assumed that ovulation does not occur and that follicles do not grow in a normal wave pattern. In truth, no study has ever looked to see whether follicles are actually growing, regressing or are arrested in women with irregular/absent menstrual cycles. By comparing follicle wave dynamics, reproductive hormones and markers of metabolism in women with regular and irregular menstrual cycles, the researchers plan to identify what factors might explain why fertility potential and long-term health are compromised in some women but not in others. Further, we will determine if any of these metabolic factors are unique to PCOS representing specific metabolic risks or follicle growth impairment. The ultimate goal of this research is to understand how body composition, nutrition and metabolism regulate follicle development in women so we can better develop lifestyle and drug therapies to help women preserve their fertility and long-term health. Since obesity has recently become the leading cause of infertility in North America, these studies are especially important.
To accomplish our objective, the investigators plan to recruit up to 40 women with regular menstrual cycles and up to 40 women with irregular/absent menstrual cycles. Our goal is to recruit an equal number of women in each group such that they are matched for age (18 - 35 years old) and body mass index (BMI; Normal weight = 18 - 24 kg/m2; Overweight = 25 - 29 kg/m2; Obese = 30kg/m2). Women will undergo serial ultrasonographic of their ovaries every other day from ovulation to ovulation in women with regular menstrual cycles or for 5 weeks in women with cycle irregularity. Blood samples will be collected at each visit. Ultrasound scans of the ovaries will be assessed for the total number, size, and distribution of follicles using ultrasound imaging techniques. Blood samples collected will be assayed to determine serum concentrations of luteinizing hormone (LH), follicle stimulating hormone (FSH), estradiol, progesterone, anti-müllerian hormone (AMH), and inhibin B. During day 3-5 in women with regular menstrual cycles or at a time where no dominant follicle or corpus luteum is present, an early morning visit will be conducted to assess the following metabolic parameters : (1) 75-gram oral glucose tolerance test to characterize glucose and insulin dynamics at 0, 30, 60, 90, and 120 minutes post-glucose ingestion; (2) dual X-ray absorptiometry (DXA) scan to quantify body fat and lean muscle distribution; (3) vitals and anthropometry assessment to measure waist and hip circumference, height, weight, blood pressure, and heart rate, and (4) fasting blood tests to detect serum concentrations of androgens (i.e., total testosterone, androstenedione, free androgen index) and serum markers of metabolic syndrome (i.e., lipids and hemoglobin A1C); (5) optional subcutaneous fat biopsy to analyze fat cells, which represent a site of reproductive hormone synthesis.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Regular menstrual cycles | – | –Adult women will be assigned to this category if they report a history of regular menstrual cycles. |
| Irregular menstrual cycles | – | –Adult women will be assigned to this category if they report a history of irregular menstrual cycles, including women with a pre-existing diagnosis of PCOS. |
Who may qualify
- Ages
- 18 to 35 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- Women must be able to transport to Cornell University in Ithaca, NY. Eligible participants are between 18-35 years with a BMI of 18 kg/m2 or higher. Women are screened and enrolled following consent based on their response to our advertisements. Enrollment is restricted to the geographical area.
Key inclusion criteria (6 listed)
- Between 18 and 35 years
- BMI ≥ 18 kg/m2
- If ≥ 21 years old, must have had healthy pelvic exam w/in past 2 years
- Regular menstrual cycles (21-35 days);
- Irregular menstrual cycles (>36 days) with or without a previous diagnosis of PCOS from a primary care provider
Key exclusion criteria (3 listed)
- Current use of medication(s) known or suspected to interfere with reproductive function (eg. oral contraceptives) or insulin sensitivity
- Pregnant or breastfeeding
- Not otherwise healthy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Follicle number
Time frame: 4-5 weeks
The number of all antral follicles in each ovary will be determined using ultrasonography for each participant. Changes in follicle number over time will be compared between groups.
Follicle diameter
Time frame: 4-5 weeks
The diameter of all follicles >2mm will be determined using ultrasonography for each participant. Changes in follicle diameter over time will be compared between groups.
16 secondary outcomes
Ovarian Volume
Time frame: 4-5 weeks
Anti-Müllerian hormone
Time frame: 4-5 weeks
Serum FSH concentration
Time frame: 4-5 weeks
Serum LH concentration
Time frame: 4-5 weeks
Serum progesterone concentration
Time frame: 4-5 weeks
LH-FSH ratio
Time frame: 4-5 weeks
Insulin sensitivity
Time frame: 1 day
Androgen concentrations
Time frame: 1 day
Menstrual Cycle Length
Time frame: 4-5 weeks
Hirsutism
Time frame: 1 day
Serum markers of metabolic syndrome
Time frame: 1 day
Blood Pressure
Time frame: 1 day
Body mass index
Time frame: 1 day
Waist-to-hip ratio
Time frame: 1 day
Body fat distribution
Time frame: 1 day
Subcutaneous fat biopsy (optional)
Time frame: 1 day
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Feb 2024.
- Derived from this study: PubMed 41868592Evans AT, Rehani E, Smith B, Hong MD, Lewin Z, Hiroshige K, Spandorfer SD, Hajirasouliha I, Lujan ME, Hoeger KM. Diagnosis of Polycystic Ovary Syndrome With Predictive Modeling of Select Clinical Features. O G Open. 2026 Mar 19;3(2):e161. doi: 10.1097/og9.0000000000000161. eCollection 2026 Apr.
- Derived from this study: PubMed 38335228Oldfield AL, Carter FE, Reeves RE, Jarrett BY, Vanden Brink H, Lujan ME. Impact of a hypocaloric dietary intervention on antral follicle dynamics in eumenorrheic women with obesity. Hum Reprod. 2024 Apr 3;39(4):801-811. doi: 10.1093/humrep/deae017.
- Derived from this study: PubMed 36708012Oldfield AL, Vanden Brink H, Carter FE, Jarrett BY, Lujan ME. Obesity is associated with alterations in antral follicle dynamics in eumenorrheic women. Hum Reprod. 2023 Mar 1;38(3):459-470. doi: 10.1093/humrep/dead007.
Related trials for Oligomenorrhea
Recruiting
This Study Aims to Evaluate Whether Milamend's Product Could Improve Hormone Balance in Women Who Suffer From Self-reported PCOS Symptoms.
Polycystic Ovarian Syndrome (PCOS)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Marla E. Lujan, PhD principal investigator
Cornell University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Oligomenorrhea and Amenorrhea, run by Cornell University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Follicle number (time frame: 4-5 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01927432, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Feb 2024.